- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00206752
Study of Unilateral Neck Irradiation in Patients With SCC of the Head and Neck (Unilateral)
A Randomized Prospective Evaluation of Unilateral/Ipsilateral Neck Irradiation in Selected Patients With Squamous Cell Carcinoma of the Head and Neck Who Are Managed by Radiation Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients will be treated with definitive external beam radiation plus/minus chemotherapy plus/minus neck dissection in the ipsilateral neck (post radiation). The primary site will be treated with definitive radiation therapy, or definitive surgery plus post-operative radiation therapy. Primary endpoints are loco-regional control, as well as quality of life, xerostomia, mucositis, and neck fibrosis.
Salivary evaluations shall be performed prior to the initiation of radiation therapy, during the second week of EBRT, and at the completion of radiation. Evaluations will also be conducted at 3, 6, and 12 months after the completion of EBRT.
Oral mucositis will be assessed prior to the initiation of EBRT and weekly during EBRT. Evaluations will also be conducted at 3 and 6 months after the completion of EBRT. Two standardized mucositis scales will be used: the RTOG scale and the WHO scale.
Clinical response will be evaluated by physical exam and PET/CT. PET/CT scans will be done at 3, 6, 12, 18, and 24 months, and then when clinically indicated during follow-up.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10003
- Beth Israel Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Squamous cell carcinoma of the oral cavity or oropharynx, with the primary lesion >1 cm from the midline.
- Patient has no clinical or radiologic evidence of contralateral neck node metastases.
- No evidence of distant metastasis.
- No previous history of radiation therapy or chemotherapy
- performance status 0-2
- Age >= 18
- Signed informed consent
- Patients must be accessible for treatment and follow-up
Exclusion Criteria:
- HIV positive patients
- Pregnancy or any patients not practicing contraception
- Active tobacco or alcohol addiction (as assessed by medical caregiver)
- Serious comorbid disease which prevents delivery of full treatment including psychiatric disorders, cardiopulmonary disease, etc.
- Concomitant use of any trial anticancer therapeutic within 30 days of entry
- Uncontrolled hypertension
- Known hypersensitivity to mammalian cell-derived products
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: unilateral radiation therapy
definitive external beam radiation in the ipsilateral neck.
|
definitive external beam radiation in the ipsilateral neck.
definitive external beam radiation in the ipsilateral neck
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
FACT (head and neck);Xerostomia related Quality of Life Questionnaire
Time Frame: September 2010
|
September 2010
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kenneth Hu, MD, Department of Radiation Oncology at Beth Israel Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 186-03
- ETH136-03D
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.